Literature DB >> 35795621

Clinical Phenotyping and the Application of Precision Medicine in MAFLD.

Saad Saffo1, Albert Do1.   

Abstract

Content available: Audio Recording.
© 2022 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2022        PMID： 35795621      PMCID： PMC9248929          DOI： 10.1002/cld.1199

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  33 in total

1.  Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.

Authors:  Mario Masarone; Jacopo Troisi; Andrea Aglitti; Pietro Torre; Angelo Colucci; Marcello Dallio; Alessandro Federico; Clara Balsano; Marcello Persico
Journal:  Metabolomics       Date:  2021-01-16       Impact factor: 4.290

2.  Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.

Authors:  Cyrielle Caussy; Veeral H Ajmera; Puneet Puri; Cynthia Li-Shin Hsu; Shirin Bassirian; Mania Mgdsyan; Seema Singh; Claire Faulkner; Mark A Valasek; Emily Rizo; Lisa Richards; David A Brenner; Claude B Sirlin; Arun J Sanyal; Rohit Loomba
Journal:  Gut       Date:  2018-12-19       Impact factor: 23.059

3.  Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.

Authors:  Janki Patel; Ricki Bettencourt; Jeffrey Cui; Joanie Salotti; Jonathan Hooker; Archana Bhatt; Carolyn Hernandez; Phirum Nguyen; Hamed Aryafar; Mark Valasek; William Haufe; Catherine Hooker; Lisa Richards; Claude B Sirlin; Rohit Loomba
Journal:  Therap Adv Gastroenterol       Date:  2016-07-05       Impact factor: 4.409

4.  PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver.

Authors:  Liyun Yuan; Norah A Terrrault
Journal:  Hepatobiliary Surg Nutr       Date:  2020-06       Impact factor: 7.293

5.  Established and emerging factors affecting the progression of nonalcoholic fatty liver disease.

Authors:  Stergios Kechagias; Patrik Nasr; Julia Blomdahl; Mattias Ekstedt
Journal:  Metabolism       Date:  2020-02-14       Impact factor: 8.694

6.  Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.

Authors:  Rohit Loomba; Robert Wong; Jeremy Fraysse; Sanatan Shreay; Suying Li; Stephen Harrison; Stuart C Gordon
Journal:  Aliment Pharmacol Ther       Date:  2020-05-05       Impact factor: 8.171

Review 7.  Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives.

Authors:  Stefano Gitto; Filippo Schepis; Pietro Andreone; Erica Villa
Journal:  Metabolites       Date:  2018-02-24

Review 8.  Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.

Authors:  Saumya Jayakumar; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2019-05-31       Impact factor: 8.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.